Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows - Astellas Pharma (O

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTC:ALPMF)
The data were presented at the American Society for Cell and Gene Therapy (ASGCT) meeting.
Data Highlights:
- HiTs are CD8 and HLA-independent and kill mesothelin expressing human tumor cells.
- Data demonstrate that the mesothelin HiT is not dependent on CD8 to kill target cells, and CD4 cells expressing the HiT are cytotoxic towards tumor cells.
- Data from additional in vitro experiments show that Adaptimmune's HiT is not neutralized by soluble mesothelin, unlike the TRuC construct.
- HiT T-cells targeting mesothelin induced complete tumor regression in a mouse xenograft tumor model and outperformed a comparator TRuC construct.
Price Action: ADAP shares are up 2.1% at $4.82 during the market trading session on the last check Tuesday.

To add Benzinga News as your preferred source on Google, click here.